Credit: Ochsner Health
Veronica Gillispie-Bell, MD, Medical Director of Quality at Ochsner Health Women's Services
The Biden Administration recently announced a new federal initiative to expand the use of medication to treat substance use disorders in pregnant women, including buprenorphine and methadone.
Dr. Veronica Gillispie-Bell, Medical Director of Quality at Ochsner Health Women’s Services, can discuss the various health risks associated with opioid dependency among pregnant women – an issue that has grown in recent years – including low birth weight, preterm labor, and miscarriages.
RSS